Wang W, Wang R, Wang Y, et al. Preoperative Colonic Lesion Localization with Charcoal Nanoparticle Tattooing for Laparoscopic Colorectal Surgery

Department of Digestive Diseases, Fuzhou General Hospital, Xiamen University, Fuzhou 350025, China.
Journal of Biomedical Nanotechnology (Impact Factor: 5.34). 12/2013; 9(12):2123-5. DOI: 10.1166/jbn.2013.1767
Source: PubMed


The efficiency and safety of charcoal nanoparticle tattooing in localizing unpalpable colonic small lesions for later laparoscopy is described. Twenty six patients were enrolled for this prospective study. Tumor sites were localized with charcoal nanoparticles during colonoscopy for later laparoscopic colorectal operations. In all patients, the entire colon was examined preoperatively by colonoscopy and 0.5 ml (5 mg) of charcoal nanoparticle was injected submucosally near lesions or polypectomy sites. During laparoscopic colorectal operations for these biopsy-proven tumors, tumors were easily identified. The mean resection margin was 3.13 +/- 2.01 cm. The mean length of resected intestinal segment was 12.69 +/- 4.39 cm. No tumor was found at the resection line as indicated by postoperative pathological examination. Most importantly, no wrong segment was resected. Thus we show that easy identification of tumor can be achieved by preoperative tattooing with charcoal nanoparticles. Further studies regarding the long-term tattooing of tumor with charcoal nanoparticles are warranted.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Individual differences in breast size are a conspicuous feature of variation in human females and have been associated with fecundity and advantage in selection of mates. To identify common variants that are associated with breast size, we conducted a large-scale genotyping association meta-analysis in 7169 women of European descent across three independent sample collections with digital or screen film mammograms. The samples consisted of the Swedish KARMA, LIBRO-1 and SASBAC studies genotyped on iCOGS, a custom illumina iSelect genotyping array comprising of 211 155 single nucleotide polymorphisms (SNPs) designed for replication and fine mapping of common and rare variants with relevance to breast, ovary and prostate cancer. Breast size of each subject was ascertained by measuring total breast area (mm(2)) on a mammogram. We confirm genome-wide significant associations at 8p11.23 (rs10086016, p=1.3×10(-14)) and report a new locus at 22q13 (rs5995871, p=3.2×10(-8)). The latter region contains the MKL1 gene, which has been shown to impact endogenous oestrogen receptor α transcriptional activity and is recruited on oestradiol sensitive genes. We also replicated previous genome-wide association study findings for breast size at four other loci. A new locus at 22q13 may be associated with female breast size.
    Journal of Medical Genetics 07/2013; 50(10). DOI:10.1136/jmedgenet-2013-101708 · 6.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Numerous studies established high mammographic density (MD) as a significant breast cancer risk. By adopting both radiological and epidemiological perspectives, we analysed the capacity of this radiological parameter to express an individual level of risk and the methods for assessing the relationship between MD categories and risk. MD is unable to identify individual underlying anatomical and physiological components. Many factors affect accurate and reproducible measurements and consequently classifications of MD. Significant relative risks were found by comparing the MD categories in the tails of distribution (i.e. the group of women with the lowest MD to that with the highest MD), which represent <10 % of women in each group: the majority of the population was ignored. When a relevant threshold of MD was applied to compare another group and the entire population was included to compare the two groups, some studies showed no significant or only moderate relative risk (RR) between women with readings above and those below the threshold. Sensitivity and specificity remain unknown. MD cannot be considered a worthwhile test by which to categorically identify high-risk women in screening. Key points • Unknown individual anatomical and physiological components do not express the risk level.• The epidemiological conditions are not relevant to distinguish a high-risk category.• The most relevant studies show no or moderate risks.
    European Radiology 06/2014; 24(10). DOI:10.1007/s00330-014-3278-7 · 4.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine the feasibility of using carbon nanoparticles to track nonpalpable breast cancer for breast-conserving surgery.During breast-conserving surgery, it is often very challenging to determine the boundary of tumor and identify involved lymph nodes. Currently used methods are useful in identifying tumor location, but do not provide direct visual guidance for resection margin during surgery.The study was approved by the Institutional Review Board of the Fuzhou General Hospital (Fuzhou, China). The current retrospective analysis included 16 patients with nonpalpable breast cancer receiving breast-conserving surgery under the guidance of preoperative marking using a carbon nanoparticle, as well as 3 patients receiving carbon nanoparticle marking followed by neoadjuvant treatment and then breast-conserving surgery. The Tumor Node Metastasis stage in the 16 cases included: T1N0M0 in 7, T1N1M0 in 2, T2N0M0 in 4, and T2N1M0 in the remaining 3 cases. The nanoparticle was injected at 12 sites at 0.5 cm away from the apparent edge under colored ultrasonography along 6 tracks separated by 60 degrees (2 sites every track). Lymph node status was also examined.The resection edge was free from cancer cells in all 16 cases (and the 3 cases with neoadjuvant treatment). Cancer cells were identified in majority of stained lymph nodes, but not in any of the unstained lymph nodes. No recurrence or metastasis was noticed after the surgery (2 to 22-month follow-up; median: 6 months).Tracking nonpalpable breast cancer with carbon nanoparticle could guide breast-conserving surgery.
    Medicine 03/2015; 94(10):e605. DOI:10.1097/MD.0000000000000605 · 5.72 Impact Factor

Similar Publications